Safety population (n = 351) | Faster infusion evaluable populationa(n = 337) | |
---|---|---|
Demographics | ||
Female, n (%) | 279 (79.5) | 268 (79.5) |
Age, mean (SD), y | 55.5 (11.5) | 55.6 (11.4) |
Range | 23-88 | 23-88 |
Age group, n (%) | ||
18-40 y | 38 (10.8) | 34 (10.1) |
41-64 y | 244 (69.5) | 236 (70.0) |
≥ 65 y | 69 (19.7) | 67 (19.9) |
Race, n (%) | ||
White | 295 (84.0) | 283 (84.0) |
African American | 35 (10.0) | 33 (9.8) |
Other | 21 (6.0) | 21 (6.2) |
Weight, mean (SD), kg | 84.9 (21.2) | 84.9 (21.2) |
Range | 47-156 | 47-156 |
Height, mean (SD), cm | 165.0 (9.6) | 165.0 (9.6) |
Range | 130-198 | 130-198 |
RA clinical characteristics | ||
Duration of RA, mean (SD), y | 12.5 (9.7) | 12.4 (9.6) |
RA disease duration, n (%) | ||
< 3 y | 42 (12.0) | 42 (12.5) |
3-4 y | 39 (11.1) | 38 (11.3) |
5-10 y | 93 (26.5) | 87 (25.8) |
> 10 y | 177 (50.4) | 170 (50.4) |
Prior rituximab treatment | ||
No. of prior rituximab courses, n (%) | ||
0 | 306 (87.2) | 293 (86.9) |
1 | 24 (6.8) | 24 (7.1) |
2 | 21 (6.0) | 20 (5.9) |
Months since most recent rituximab course, n | 45 | 44 |
Mean (SD) | 6.8 (0.9) | 6.7 (0.9) |
Range | 5-9 | 5-9 |
Medication history | ||
No. of prior anti-TNF agents, n (%) | ||
0 | 4 (1.1) | 4 (1.2) |
1 | 187 (53.3) | 182 (54.0) |
2 | 116 (33.0) | 108 (32.0) |
≥ 3 | 44 (12.5) | 43 (12.8) |
Prior non–anti-TNF biologic DMARDs | ||
Abatacept | 17 (4.8) | 16 (4.7) |
Tocilizumab | 12 (3.4) | 12 (3.6) |
MTX dose, mg/wk | ||
Mean (SD) | 17.4 (4.7) | 17.3 (4.7) |
Median (range) | 17.5 (8–25) | 17.5 (8–25) |
Oral steroid use, n (%) | 150 (42.7) | 143 (42.4) |
Oral steroid dose, mg/d | ||
Mean (SD) | 7.2 (3.4) | 7.3 (3.4) |
Median (range) | 5 (2–25) | 5 (2–25) |